Birchview Capital’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-100,827
| Closed | -$910K | – | 83 |
|
|
2025
Q4 | $910K | Buy |
100,827
+2,000
| +2% | +$14.9K | 0.53% | 44 |
|
|
2025
Q3 | $307K | Buy |
98,827
+70,027
| +243% | +$186K | 0.23% | 58 |
|
|
2025
Q2 | $61.6K | Hold |
28,800
| – | – | 0.06% | 66 |
|
|
2025
Q1 | $33.1K | Hold |
28,800
| – | – | 0.03% | 67 |
|
|
2024
Q4 | $63.1K | Hold |
28,800
| – | – | 0.05% | 65 |
|
|
2024
Q3 | $62.8K | Hold |
28,800
| – | – | 0.05% | 57 |
|
|
2024
Q2 | $66.5K | Hold |
28,800
| – | – | 0.06% | 57 |
|
|
2024
Q1 | $158K | Hold |
28,800
| – | – | 0.13% | 53 |
|
|
2023
Q4 | $71.1K | Buy |
28,800
+2,400
| +9% | +$22.8K | 0.06% | 57 |
|
|
2023
Q3 | $917K | Hold |
26,400
| – | – | 0.78% | 22 |
|
|
2023
Q2 | $866K | Hold |
26,400
| – | – | 0.65% | 27 |
|
|
2023
Q1 | $884K | Buy |
26,400
+4,400
| +20% | +$171K | 0.69% | 21 |
|
|
2022
Q4 | $721K | Sell |
22,000
-23,000
| -51% | -$681K | 0.51% | 27 |
|
|
2022
Q3 | $1.57M | Buy |
45,000
+12,000
| +36% | +$266K | 1.11% | 19 |
|
|
2022
Q2 | $404K | Buy |
33,000
+8,000
| +32% | +$120K | 0.29% | 42 |
|
|
2022
Q1 | $339K | Hold |
25,000
| – | – | 0.24% | 47 |
|
|
2021
Q4 | $497K | Buy |
+25,000
| New | +$474K | 0.32% | 44 |
|
Other funds holding VTYX
Birchview Capital's VTYX Position: Q1 2026 in Review
Birchview Capital sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 100,827 shares — an estimated $910K sold.
Birchview Capital first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $1.57M in Q3 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Birchview Capital reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Birchview Capital sold 100,827 Ventyx Biosciences shares in Q1 2026, an estimated $910K.
- Birchview Capital first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Birchview Capital's Ventyx Biosciences position peaked at $1.57M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.